Prof. Peter Fuhr, MD
Position(s)
Senior Consultant
Department of Neurology
Institution
University Hospital Basel
Phone +41 61 328 61 63
Research Group Peter Fuhr
Research Focus
Neurology
Area of Research
Prognosis and follow-up of chronic CNS diseases (Parkinson's, multiple sclerosis), especially applying neurophysiological parameters and risk factors.
Approved Research Projects
- Integrating Automated EEG Analysis & Standardized Reporting in Clinical Diagnostics & Longitudinal Monitoring, PI: Keller, Fuhr. F: SNF
- Computer aided Methods for Diagnosis and Early Risk Assessment for Parkinson`s Disease Dementia, PI: Roth, Fuhr. F: SNF
- Improved prediction and monitoring of central nervous system disorders with advanced neurophysiological and genetic assessment, PI: Fuhr. F: SNF
- High frequency and intensive prevention program for cognitive stabilization and improving of quality of life in Parkinson’s disease patients, PI: Fuhr. F: Parkinson Schweiz
Collaborations
National Collaborations
- Prof. Dr. Volker Roth, Department of Mathematics and Computer Science, University of Basel, Basel.
- Prof. Dr. Simone Hemm, School of Life Sciences FHNW, Institute for Medical Engineering and Medical Informatics, Muttenz.
- Prof. Dr. Roselind Lieb, Faculty of Psychology, University of Basel, Basel.
International Collaborations
- Dr. Mahmoud Hassan, Research Scientist, Rennes, France.
- Prof. Dr. med. Tonio Ball, University of Freiburg, Freiburg, Germany.
- Prof. Inga Liepelt, Senior Researcher at the Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, Tübingen, Germany.
- Prof. Claudio Babiloni, Sapienza University of Rome, Rome, Italy.
Ongoing Research Projects
- Integrating Automated EEG Analysis & Standardized Reporting in Clinical Diagnostics & Longitudinal Monitoring, PI: Keller, Fuhr. F: SNF
- Computer aided Methods for Diagnosis and Early Risk Assessment for Parkinson`s Disease Dementia, PI: Roth, Fuhr. F: SNF
- High frequency and intensive prevention program for cognitive stabilization and improving of quality of life in Parkinson’s disease patients, PI: Fuhr. F: Parkinson Schweiz
- A Randomized, Multicenter, Double-Blind, Placebocontrolled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease, PI: Fuhr. F: Roche.
Research Team
Mira Atanasova, MSc
Scientific Employee
Phone -
Email -